Possible modulatory effect of endogenous islet catecholamines on insulin secretion

Maria I Borelli and Juan J Gagliardino*

Address: CENEXA – Center of Experimental and Applied Endocrinology (National University of La Plata-National Research Council, PAHO/WHO Collaborating Center), School of Medical Sciences, 60 y 120, 1900 La Plata, Argentina
E-mail: Maria I Borelli - celine@netverk.com.ar; Juan J Gagliardino* - gagliardino@infovia.com.ar

*Corresponding author

Abstract

Background: The possible participation of endogenous islet catecholamines (CAs) in the control of insulin secretion was tested.

Methods: Glucose-induced insulin secretion was measured in the presence of 3-Iodo-L-Tyrosine (MIT), a specific inhibitor of tyrosine-hydroxylase activity, in fresh and precultured islets isolated from normal rats. Incubated islets were also used to measure CAs release in the presence of low and high glucose, and the effect of α2-(yohimbine [Y] and idazoxan [I]) and α1-adrenergic antagonists (prazosin [P] and terazosin [T]) upon insulin secretion elicited by high glucose.

Results: Fresh islets incubated with 16.7 mM glucose released significantly more insulin in the presence of 1 µM MIT (6.66 ± 0.39 vs 5.01 ± 0.43 ng/islet/h, p < 0.02), but did not affect significantly the insulin response to low glucose. A similar enhancing effect of MIT upon insulin secretion was obtained using precultured islets devoid of neural cells, but absolute values were lower than those from fresh islets, suggesting that MIT inhibits islet rather than neural tyrosine hydroxylase. CAs concentration in the incubation media of fresh isolated islets was significantly higher in the presence of 16.7 than 3.3 mM glucose: dopamine 1.67 ± 0.13 vs 0.69 ± 0.13 pg/islet/h, p < 0.001, and noradrenaline 1.25 ± 0.17 vs 0.49 ± 0.04 pg/islet/h, p < 0.02. Y and I enhanced the release of insulin elicited by 16.7 mM glucose while P and T decreased such secretion.

Conclusion: Our results suggest that islet-originated CAs directly modulate insulin release in a paracrine manner.

Background

Insulin secretion in response to glucose is modulated by neural [1], hormonal and paracrine [2] factors that bestow great precision to the stimulus: secretion coupling process. Catecholamines (CAs) contribute to this mechanism by exerting a direct and dual effect on the B-cell to induce either inhibition or stimulation of insulin secretion through their interaction with α2 or α1 and β2 adrenergic receptors, respectively [3,4]. Since islet B-cells have more α2 than α1 and β2 adrenergic receptors, physiological concentrations of CAs will bind mainly to the α2 population receptors and thus inhibit insulin secretion [5–8].

Although the effect of the sympathetic nervous system (SNS) and of circulating CAs on islet physiology has been...
studied in both normal and pathological states, little is known about the possible participation of endogenously-generated CAs in the control of islet function. Islet cells have been shown to contain enzymes involved both in the synthesis of CAs – tyrosine hydroxylase (TH) [9,10] and dihydroxyphenylalanine (DOPA) decarboxylase [11,12] – and in their inactivation – monoamine oxidase [13,14].

We have recently measured TH activity in normal rat isolated islets, showing an increase in the enzyme’s activity, and a decrease of CAs content and insulin release in rats fed only with carbohydrates [15]. In these experiments, comparable TH activity values were measured in islets isolated from either control or solarectomized rats, thus suggesting that the enzyme activity was of islet rather than neural origin.

In order to gain evidence about the possible modulatory role of CAs of endogenous islet origin as paracrine hormonal regulators of insulin secretion, we have currently studied: a) The effect of 3-Iodo-L-Tyrosine (MIT) – a selective drug usually used for the acute inhibition of TH in neuroendocrine tissues [16] – on the insulin secretory response of either fresh or precultured isolated islets to glucose, and b) The effect of specific α2- or α1-adrenergic receptor antagonists upon glucose-induced insulin secretion in isolated islets, and c) The release of endogenous CAs by endocrine islet cells.

Methods

Chemicals and drugs

Collagenase was obtained from Serva Feinbiochemica, (Heidelberg, Germany), while bovine serum albumin, fraction V and other reagents of the purest available grade were purchased from Sigma Chemical Co. (St. Louis, USA).

Animals and islet isolation

Male Wistar rats (180–200 g) were used as a source of islets. They were fed ad libitum and kept under conditions of controlled temperature and lighting (12 h light and 12 h dark). After enzymatic digestion with collagenase, pancreases were repeatedly washed and the islets rapidly hand-picked with siliconized glass pipettes under a dissecting microscope [17].

Islet culture

Isolated islets were cultured at 37°C in a humidified atmosphere for 24 h in plastic Petri dishes (NUNC) with RPMI 1640 supplemented with Heps (20 mM), CO(HNa (4.1 mM), penicillin, streptomycin (100.000 U/ I and 100 mg/I, respectively), 10% newborn calf serum [18], and 3 mM glucose. The pH was adjusted to 7.4. After the first 24-h period, the culture medium was replaced by fresh medium with the same glucose concentration; afterwards, the medium was changed every second day until accomplishing the total one-week culture period.

Islet incubation

Groups of 5 fresh or precultured isolated islets were incubated for 30 min at 37°C in 600 µl Krebs-Ringer-bicarbonate buffer with 1% (w/v) bovine-serum albumin, Trasylol™ (400 IU/ml), and either 3.3 or 16.7 mM glucose, with or without MIT (1 µM) [19]. The medium had been previously gassed with a mixture of 5% CO2:95% O2 (v/v) to adjust the pH to 7.4.

Separately, groups of 5 fresh isolated islets were incubated for 60 min in the presence of α2-(yohimbine [Y, 0.1 and 1 µM] or idazoxan [I, 1 µM]) and α1-(prazosin [P, 0.1 and 0.5 µM] or terazosin [T, 0.1 and 0.5 µM]) adrenergic antagonists. In all cases, aliquots from the medium were obtained at the end of the incubation period and kept frozen until insulin determination by radioimmunoassay [20].

CAs quantitation

Another group of islets was incubated for 30 min in the presence of 3.3 and 16.7 mM glucose. Following that incubation period, CAs were measured in the incubation media after partial purification by batch alumina extraction, separated by reverse-phase high-pressure liquid chromatography on a 4.6 X 250-mm Zorbax Rp C18 column (DuPont), and quantified amperometrically with a triple-electrode system (ESA, Bedford, NA) by measuring the current produced upon exposure of the column effluent to first oxidizing and then reducing potentials in series [21].

Data analysis

For the statistical evaluation of the data, we employed both variance analysis and the paired Student t-test.

Results

The addition of 1 µM MIT to the incubation medium of fresh isolated islets enhanced significantly the release of insulin elicited by 16.7 mM glucose (Fig. 1, upper pannel; p < 0.02). Such effect was not observed in the presence of a low glucose concentration. Similarly, MIT enhanced significantly the release of insulin elicited by high glucose in precultured islets (Fig. 1, lower pannel; p < 0.05). In this case, however, the absolute insulin concentration values measured in the incubation media were lower than those measured in the experiments performed with fresh islets.

The assessment of CAs in the incubation media from freshly isolated islets showed a glucose-induced increase
Addition of selective $\alpha_2$- and $\alpha_1$- CA receptor antagonists to the medium significantly affected the insulin released by islets incubated with glucose: $\alpha_2$-antagonists Y (0.1 and 1 µM) and I (1 µM) enhanced significantly the release of insulin in response to 16.7 mM glucose (p < 0.05 and 0.001, respectively; Fig. 2, upper panel), while $\alpha_1$-antagonists P and T (0.1 and 0.5 µM) decreased it significantly (P, p < 0.02 and 0.005, and T, p < 0.001 and 0.001, respectively; Fig. 2, lower panel). Excepting I, the effect of the antagonists was dose-dependent: insulin release increased 82, 171 and 895 % in the presence of 0.1 and 1 µM Y and 1 µM I, respectively, while it decreased 40 and 49% with 0.1 and 0.5 µM P, and 51 and 45% in the presence of T at the same concentrations.

Discussion
In our experiments, MIT addition to the incubation medium induced a significant increase in glucose-induced insulin release, either from fresh or precultured isolated islets. Incubation of different tissues with MIT, for even shorter periods than the one we used, blocks significantly the activity of TH, the first limiting step enzyme in CA biosynthesis [16]. The presence of immunocytochemically demonstrable TH in α and B islet cells has been reported in fetal-mouse pancreases [9], and in the B-cells of several adult rodents (Sprague Dawley rats, two strains of mice, and pigmented guinea pigs) [10]. Further, we have measured TH activity in the endocrine pancreas of normal adult rats, recording comparable TH activity values in islets isolated from either control or solarectomized rats (330 ± 40 vs 300 ± 80 pmol/mg protein/h), indicating that the TH activity measured was of islet rather than neural origin [15]. We could then assume that as in other tissues, TH inhibition by MIT decreases CA production rate in the islets, and consequently its availability [22]. Following this reasoning, it could be argued that, at least in our model, CAs synthesis (or availability) participates in the regulation of insulin secretion.

Our cultured islets would be devoid of adrenergic innervation since sympathetic neurons maintained in a culture medium with a Ca$^{2+}$ concentration above 2 mM (condition employed in our islet culture) do not survive more than 6–8 days [23]. Since the blocking effect of MIT was also observed using cultured islets, we can assume that islet rather than neural CAs biosynthesis is involved in this modulatory process of insulin secretion. We cannot however completely exclude the possibility that MIT could affect insulin secretion either directly or by modifying other processes than CAs biosynthesis.

There is considerable evidence in the literature for the possible presence of CAs biosynthesis in islet tissue: a) We have recently reported the immunocytochemical identification of DOPA decarboxylase in glucagon-containing cells of normal adult rat islets [12]; b) Oomori et al. have reported the presence of dopamine beta-hydroxylase immunoreactivity in rat pancreatic cells which – according to their features – were neither neural nor endocrine cells, and suggested that these cells may release norepinephrine (NE) to adequate stimuli [24]; c) Lundquist et al. detected dopamine in islets obtained from chemically-sympathectomized mice by means of high-performance liquid chromatography [25]; and d) Falck and Hellman showed that B-cells from guinea-pig islets

![Figure 1](http://www.biomedcentral.com/1472-6823/1/1)
The secretion of insulin elicited by glucose in a dose-dependent manner. The adrenoceptor blockade by Y increased the secretion of insulin by 82 and 172% while I enhanced such secretion by 895%. Conversely, P and T diminished insulin secretion by 40–49% and 51–45%, respectively, with the doses currently employed. As shown by other authors, the uneven effect of adrenergic antagonists could be ascribed to the relative abundance or activity of $\alpha_2$-adrenoceptors in B-cells, as compared with $\alpha_1$- and $\beta_2$-adrenoceptors [5–8]. On the other hand, Schuit et al. showed that P was ineffective in both a and B-cells [31]; such discrepancy with our results can be attributed to the method used in each case.

Since we did not add CAs to the incubation media, it could be assumed that the effect of the antagonists was due to an interference with the action of CAs, elaborated and co-released with insulin by endocrine islet cells. The results presented here as well our previous report on the glucose-induced release of CAs by isolated rat islets [32] support this assumption. On account of these results, therefore, we postulate that islet-originated CAs could directly modulate the release of insulin in a paracrine hormonal manner.

### Competing interests
None declared.

### Acknowledgements
This work was partially supported with funds provided by CONICET from Argentina. The authors thank Dr I Armando and Dr M Barontini (CEDIE – Centro de Investigaciones Endocrinológicas, CONICET) for catecholamine determinations, A Díaz for technical assistance, and A Di Maggio for careful secretarial support.

### References
1. Woods SC, Porte D Jr: Neural control of the endocrine pancreas. Physiol Rev 1974, 54:596-619
2. Pipeleers DG, Schuit FC, in’t Veld PA, Maes E, Hooghe-Peters EL, van de Winkel M, Gepts W: Interplay of nutrients as hormones in the regulation of insulin release. Endocrinology 1985, 117:824-833
3. Skoglund G, Lundquist I, Ahren B: Effects of alpha 1- and alpha 2-adrenoceptor stimulation and blockade on plasma insulin levels in the mouse. Pancreas 1986, 1:415-420
4. Ahren B, Taborsky GJ Jr, Porte D Jr: Neuropetidependent versus cholinergic and adrenergic regulation of islet hormone secretion. Diabetologia 1986, 29:827-836
5. Ahren B, Lundquist I, Jaruht J: Effects of alpha 1-, alpha 2- and beta-adrenoceptor blockers on insulin secretion in the rat. Acta Endocrinol (Copenh) 1984, 105:78-82
6. Nakaki T, Nakadata T, Ishii K, Kato R: Postsynaptic alpha 2-adrenoceptor receptors in isolated rat islets of Langerhans: inhibition of insulin release and cyclic 3’5’-adenosine monophosphate accumulation. J Pharmacol Exp Ther 1981, 216:607-612
7. Lacy RJ, Chan SL, Cable HC, James RF, Ferrett CW, Scarpello JH, Morgan NG: Expression of alpha 2- and beta-adrenoceptor subtypes in human islets of Langerhans. J Endocrinol 1996, 148:331-543
8. Ahren B: Autonomic regulation of islet hormone secretion – implications for health and disease. Diabetologia 2000, 43:393-410
9. Teitelman G, Alpert S, Polak JM, Martinez A, Hanahan D: Precursor cells of mouse endocrine pancreas coexpress insulin, gluca-
gon, and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. Development 1993, 118:1021-1039.

10. Iturriza FC, Thibaut J: Immunohistochemical investigation of tyrosine-hydroxylase in the islets of Langerhans of adult mice, rats, and guinea pigs. Neuroendocrinology 1993, 57:476-480.

11. Teitelman G, Lee JK, Alpert S: Expression of cell type-specific markers during pancreatic development in the mouse: implications for pancreatic cell lineages. Cell Tissue Res 1987, 250:435-439.

12. Borelli MI, Villar MJ, Orezzoli A, Gagliardino JJ: Presence of DOPA decarboxylase and its localisation in adult rat pancreatic islet cells. Diabetes Metab 1997, 23:161-163.

13. Stenström A, Panagiotidis G, Lundquist I: Monoamine oxidase (MAO) in pancreatic islets of the mouse: some characteristics and the effect of chemical sympathectomy. Diabetes Res 1989, 11:81-84.

14. Stenström A, Lundquist I: Monoamine oxidase (MAO) A and B in pancreatic islets from the mouse. Biogenic Amines 1990, 6:547-555.

15. Gagliardino JJ, Borelli MI, Rubio M: Possible role of endogenous islet catecholamines in the paracrine control of insulin secretion. Diabetesologia 1996, 39 (Suppl 1):A123.

16. Smythe GA, Bradshaw JE: Different acute effects of the tyrosine hydroxylase inhibitors alpha-methyl-p-tyrosine and 3-yodo-L-tyrosine on hypothalamic noradrenaline activity and adrenocorticotrophin release in the rat. Aust J Biol Sci 1983, 36:519-523.

17. Lacy PE, Kostianovsky M: Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967, 16:35-39.

18. Brunstedt J, Nielsen JH: Direct long-term effect of hydrocortisone on insulin and glucagon release from mouse pancreatic islets in tissue culture. Acta Endocrinol (Copenh) 1981, 96:498-504.

19. Gagliardino JJ, Nierle C, Pfeiffer EF: The effect of serotonin on in vitro insulin secretion and biosynthesis in mice. Diabetesologia 1974, 10:411-414.

20. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ: Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965, 25:1375-1384.

21. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ: Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenyllglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986, 32:2030-2033.

22. Levitt M, Spector S, Sjoerdum A, Udenfriend S: Elucidation of the rate-limiting step in norepinephrine biosynthesis in the perfused guinea pig heart. J Pharmacol Exp Ther 1965, 148:1-8.

23. Wakade TD, Przywara DA, Kulkarni JS, Wakade AR: Morphological and transmitter release properties are changed when sympathetic neurons are cultured in low Ca2+ culture medium. Neuroscience 1995, 67:967-976.

24. Oomori Y, Iuchi H, Ishikawa K, Satoh Y, Ono K: Immunocytochemical study of tyrosine hydroxylase and dopamine-beta-hydroxylase immunoreactivities in the rat pancreas. Histochemistry 1994, 101:313-323.

25. Lundquist I, Ahren B, Hansson C, Hakanson R: Monoamines in pancreatic islets of guinea pig, hamster, rat, and mouse determined by high performance liquid chromatography. Pancreas 1989, 4:662-667.

26. Falck B, Hellman B: A fluorescent reaction for monoamines in the insulin producing cells of the guinea pig. Acta Endocrinol (Copenh) 1964, 1:133-138.

27. Falck B, Hellman B: Evidence for the presence of biogenic amines in pancreatic islets. Experientia 1963, 19:139-140.

28. Ahren B, Lundquist I: Effects of selective and non-selective beta-adrenergic agents on insulin secretion in vivo. J Pharmacol 1981, 71:93-104.

29. Chan SL, Perrett CW, Morgan NG: Differential expression of alpha 2-adrenoceptor subtypes in purified rat pancreatic islet A- and B-cells. Cell Signal 1997, 9:71-78.

30. Lacey RJ, Berrow NS, Scarpello JH, Morgan NG: Selective stimulation of glucagon secretion by beta(2)-adrenoceptors in isolated islets of Langerhans of the rat. Br J Pharmacol 1991, 103:1824-1828.

31. Schuit FC, Pipeleers DG: Differences in adrenergic recognition by pancreatic A and B cells. Science 1986, 232:875-877.

32. Borelli MI, Armando I, Barontini M, Gagliardino JJ: Effect of islet catecholamine release on insulin secretion. Diabetologia 1997, 40(Suppl 1):A107.